SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank50
3Y CAGR-5.5%
5Y CAGR+15.4%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
-5.5%/yr
Annual compound
5Y CAGR
+15.4%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$13.84M+49.3%
2024$9.28M-61.0%
2023$23.80M+45.3%
2022$16.38M-4.1%
2021$17.09M+152.3%
2020$6.77M+65.3%
2019$4.10M-